Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum GL-5 + lactobacillus plantarum LZU-J-TSL 6
- Development stage
- Preclinical
- Lead developer
- Lanzhou University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum GL-5 + Lactobacillus plantarum LZU-J-TSL 6 is a psychobiotic combination consisting of two specific strains of the probiotic species *Lactobacillus plantarum* (recently reclassified as *Lactiplantibacillus plantarum*). Developed by researchers at the School of Life Science, Lanzhou University, this microbial therapy is being investigated for its potential to alleviate symptoms of depression and anxiety. The mechanism of action involves the gut-brain axis, where the bacteria modulate the composition of the gut microbiota and increase the production of short-chain fatty acids (SCFAs). These changes are associated with the restoration of neurotransmitter levels, such as serotonin (5-HT), and the upregulation of brain-derived neurotrophic factor (BDNF) in the hippocampus, which collectively reduce neuroinflammation and improve behavioral outcomes in preclinical models.
- Other names
- Lactiplantibacillus plantarum GL-5 + Lactiplantibacillus plantarum LZU-J-TSL 6
02
Targets
5-HT (Serotonin receptors)BDNF (Brain-derived neurotrophic factor)
Beyond the preview
Go deeper on lactobacillus plantarum GL-5 + lactobacillus plantarum LZU-J-TSL 6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum GL-5 + lactobacillus plantarum LZU-J-TSL 6.